News-Medical.net The study found that patients who started treatment with a sulfonylurea (SFU), a dipeptidyl peptidase-4 (DPP-4) inhibitor, and a thiazolidinedione (TZ...
Everyday Health Sulfonylurea stimulates the release of insulin from the pancreas. While the medication does work quickly, it may cause severe low blood sugar, weight gain, nausea, and skin rashes. TZD, or Thiazolidinedione , helps improve the body's sensitivity to ... and more »
American Pharmacists Association, pharmacist.com ... as dulaglutide include the low risk of hypoglycemia, especially when administered with metformin or a thiazolidinedione ; the weight-loss effects of these agents; and potential adherence benefits associated with drugs that only require once-weekly ...
The Pharmaceutical Journal Only 24.5% of patients on metformin needed a second glucose-lowering medication , compared with 37.1% given a sulfonylurea, 39.6% treated with a thiazolidinedione and 36.2% with a DPP-4 inhibitor. For the latter three drugs , metformin was the most ...
WebMD The researchers found that around 40 percent of people taking a sulfonylurea, a thiazolidinedione , or a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor) added ...
Diabetes In Control While 24.5% patients on metformin required an add-on oral medication , 37.1% of patients on sulfonylurea, 39.6% of patients on thiazolidinedione , and 36.2% patients on DPP-4 inhibitor required an add-on oral medication . Moreover, 5.1% of patients on ...
